OPKO Health (OPK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
15 May, 2026Voting matters and shareholder proposals
Proposal to approve the 2026 Equity Incentive Plan, as the previous 2016 plan expired in February 2026 and no shares remain available under it.
Board recommends voting in favor of the new equity plan to enable continued equity-based compensation.
If the new plan is not approved, the company will be unable to grant new equity awards, potentially increasing cash compensation and reducing alignment with investors.
Shareholders can change or revoke their proxy votes before the annual meeting through several methods, including submitting a new proxy card or voting virtually.
Executive compensation and say-on-pay
Long-term equity-based compensation is a significant part of the overall compensation program for directors, executives, and employees.
Expiration of the previous plan may lead to increased cash compensation if the new plan is not approved.
The new plan is intended to help attract, retain, and motivate key talent.
Board of directors and corporate governance
The board has reaffirmed its recommendation to approve the 2026 Equity Incentive Plan.
Latest events from OPKO Health
- Q2 2026 revenue rose, losses narrowed, and cash reserves strengthened amid pipeline and partnership gains.OPK
Q2 2026 - All proposals passed; clinical pipeline and cash flow strong; $98M buyback authorization remains.OPK
AGM 2026 - Multiple clinical milestones expected in 2024-2025, including key data from MDX-2001 and Merck EBV vaccine.OPK
Jefferies Global Healthcare Conference 2026 - Advancing a broad clinical pipeline and global partnerships, supported by strong financials.OPK
Corporate presentation - Proxy seeks approval for director elections, new equity plan, executive pay, and auditor ratification.OPK
Proxy filing - Key votes include board elections, equity plan approval, say-on-pay, and auditor ratification.OPK
Proxy filing - Q4 revenue dropped post-divestiture, but R&D and pharma growth support a strong 2026 outlook.OPK
Q4 2025 - Q3 2025 saw a major asset sale, higher operating income, and strong cash reserves.OPK
Q3 2025 - Q1 2025 saw lower losses, strong cash, asset sales, and a $225M oncology deal with LabCorp.OPK
Q1 2025